Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma
Jorge J. Castillo(Dana-Farber Cancer Institute), Michele Bibas(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Kate Cwynarski(Royal London Hospital), Guillaume Cartron(Hôpital Saint Eloi), Daan Dierickx(KU Leuven), Yevgeny Linnik(Dartmouth–Hitchcock Medical Center), Renzo Mogollon(Universidad de San Martín de Porres), Emmanuelle Tchernonog(Centre Hospitalier Universitaire de Montpellier), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Francesco Baldini(Nello Carrara Institute of Applied Physics), Adam J. Olszewski(Memorial Hospital of Rhode Island), Pasquale L. Fedele(Monash Health), John L. Reagan(Vanderbilt University), Thomas A. Guerrero-Garcia(St. Elizabeth's Medical Center), Michael Gilbertson(Monash Health), Thomas Tousseyn(KU Leuven), Frederick Lansigan(Dartmouth College), George Grigoriadis(Hudson Institute of Medical Research), Slavisa Ninkovic(University College Hospital)
USMP Repository (Universidad de San Martín de Porres)
February 3, 2019
Cited by 13
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|New England Journal of Medicine|2015|937
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718